Sagent Pharmaceuticals, Inc. Announces the Launch of Leucovorin Calcium for Injection  
10/29/2012 7:13:02 AM

SCHAUMBURG, Ill., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Leucovorin Calcium for Injection, a folic acid derivative, and an adjuvant in antineoplastic agent therapy, in four latex-free and preservative-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Leucovorin Calcium for Injection approximated $14 million. As with all products in Sagent's portfolio, Leucovorin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.